Americans will have access to Zepbound and Wegovy at reduced prices starting in 2026.
The wildly popular treatments for diabetes and obesity will be available to consumers at a nearly 90 percent discount in January, under an agreement negotiated by the Trump administration with Eli Lilly and Novo Nordisk.
The drugs will also be sold to the Medicare program at reduced prices in July, enabling expanded coverage. State Medicaid programs will see savings as they opt into the agreement.
More than 16 million Americans have used Wegovy, Zepbound, or a comparable injectable weight-loss drug. Wegovy accounted for more than a quarter of all weight-loss prescriptions in 2024….